Shanghai Yizhong Pharmaceutical Valuation

Is 688091 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688091 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688091 (CN¥41.5) is trading above our estimate of fair value (CN¥0.25)

Significantly Below Fair Value: 688091 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688091?

Key metric: As 688091 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688091. This is calculated by dividing 688091's market cap by their current earnings.
What is 688091's PE Ratio?
PE Ratio	129.5x
Earnings	CN¥65.60m
Market Cap	CN¥8.49b

688091 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	31.3x
Enterprise Value/EBITDA	135.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 688091's PE Ratio compare to its peers?

The above table shows the PE ratio for 688091 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.8x
688076 Jiangsu Sinopep-Allsino Biopharmaceutical	27.2x	31.4%	CN¥11.5b
605116 Aurisco PharmaceuticalLtd	25.2x	27.4%	CN¥8.6b
603439 Guizhou Sanli PharmaceuticalLtd	16.2x	21.4%	CN¥5.3b
300705 Hunan Jiudian Pharmaceutical	22.6x	25.5%	CN¥11.5b
688091 Shanghai Yizhong Pharmaceutical	129.5x	n/a	CN¥8.5b

Price-To-Earnings vs Peers: 688091 is expensive based on its Price-To-Earnings Ratio (129.5x) compared to the peer average (22.8x).

Price to Earnings Ratio vs Industry

How does 688091's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688091 is expensive based on its Price-To-Earnings Ratio (129.5x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 688091's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688091 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	129.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688091's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

-2.6%

13.6%